Director at Avalo Therapeutics (AVTX) gains 3,166 common shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Avalo Therapeutics director Jonathan Goldman exercised restricted stock units into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of Avalo Therapeutics common stock at an exercise price of $0.00 per share. This reflects a derivative exercise, not an open-market purchase or sale.

According to prior grant terms, Goldman received 9,500 restricted stock units on August 13, 2024, vesting in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent on continued service.

Insider Trade Summary

3,166 shares exercised/converted

Mixed 2 txns

Insider Goldman Jonathan

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	3,166	$0.00	--
Exercise	Common Stock	3,166	$0.00	--

Holdings After Transaction: Restricted Stock Units — 3,167 shares (Direct); Common Stock — 3,166 shares (Direct)

Footnotes (1)

Restricted stock units convert into common stock on a one-for-one basis. On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.

Key Figures

RSUs Exercised: 3,166 units Common Shares Acquired: 3,166 shares Original RSU Grant: 9,500 units +2 more

5 metrics

RSUs Exercised 3,166 units Restricted stock units converted on March 28, 2026

Common Shares Acquired 3,166 shares Common stock received from RSU conversion at $0.00 per share

Original RSU Grant 9,500 units RSUs granted on August 13, 2024

Vesting Schedule 1/3 each year Vesting on March 28, 2025, 2026, and 2027

Post-transaction Common Shares 3,166 shares Common stock holding following reported transaction

Key Terms

Restricted Stock Units, derivative security, vesting, one-for-one basis

4 terms

Restricted Stock Units financial

"Restricted stock units convert into common stock on a one-for-one basis."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vesting financial

"vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

one-for-one basis financial

"Restricted stock units convert into common stock on a one-for-one basis."

Form 4 Insider Transactions: What Each Field Means →

03/31/2026 - 04:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goldman Jonathan

(Last)

(First)

(Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/28/2026		M		3,166	A	⁽¹⁾	3,166	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	03/28/2026		M			3,166	⁽²⁾	⁽²⁾	Common Stock	3,166	$0	3,167	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Avalo Therapeutics (AVTX) report for Jonathan Goldman?

Avalo Therapeutics reported that director Jonathan Goldman exercised 3,166 restricted stock units into 3,166 common shares. This was a derivative exercise at $0.00 per share, reflecting equity compensation vesting rather than an open-market stock purchase or sale.

How many Avalo Therapeutics (AVTX) shares did Jonathan Goldman acquire in this Form 4?

Jonathan Goldman acquired 3,166 shares of Avalo Therapeutics common stock through the conversion of 3,166 restricted stock units. The units converted on a one-for-one basis at an exercise price of $0.00, consistent with standard restricted stock unit award mechanics.

What are the vesting terms of Jonathan Goldman’s Avalo Therapeutics (AVTX) RSU grant?

Goldman was granted 9,500 restricted stock units on August 13, 2024, vesting in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027. Vesting is conditioned on his continued service through each respective vesting date.

Does Jonathan Goldman’s Avalo Therapeutics (AVTX) Form 4 show any stock sales?

The Form 4 shows no stock sales. It reports a derivative exercise where 3,166 restricted stock units converted into 3,166 common shares at $0.00 per share. This is a compensation-related equity conversion, not an open-market disposition of Avalo Therapeutics stock.

Are Jonathan Goldman’s Avalo Therapeutics (AVTX) restricted stock units cash-settled or share-settled?

The restricted stock units are share-settled, converting into Avalo Therapeutics common stock on a one-for-one basis. In this transaction, 3,166 restricted stock units converted into 3,166 common shares, consistent with the one-for-one conversion feature described in the award footnote.